Endologix Inc.

261 articles with Endologix Inc.

• Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018

  4/3/2018

  Endologix Inc. announced that it will report financial results for the first quarter of fiscal year 2018 after the market close on Wednesday, May 2, 2018.

• Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

  3/19/2018

  Endologix Inc. announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation® Abdominal Stent Graft Systems.

• John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.

  2/21/2018

  Endologix, Inc. announced today that John McDermott is stepping down as the Company’s Chief Executive Officer.

• Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results

  2/21/2018

  Endologix, Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

• Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study

  2/5/2018

  Endologix announced today the completion of enrollment in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study.

• Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  1/29/2018

  Endologix announced today that it has appointed Greg Morrow as the Company’s Chief Marketing Officer, effective immediately.

• Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018

  1/26/2018

  The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

• Endologix Reports Third Quarter 2017 Financial Results

  11/8/2017

  Global revenue in the third quarter of 2017 was $46.0 million, an 11.8% decrease from $52.1 million in the third quarter of 2016.

• Endologix To Announce Third Quarter 2017 Financial Results On November 7, 2017

  10/11/2017

• Endologix Receives IDE Approval For The EVAS2 Confirmatory Clinical Study To Evaluate The Nellix Endovascular Aneurysm Sealing System

  10/6/2017

• Endologix Announces CE Mark Approval For The Nellix Endovascular Aneurysm Sealing System With The Refined Indications For Use

  9/21/2017

• Endologix Announces Collaboration Agreements With Japan Lifeline For The Development And Commercialization Of Thoracic Endovascular Systems In Japan

  9/11/2017

• Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

  8/17/2017

• Endologix Reports Second Quarter 2017 Financial Results

  8/3/2017

• Endologix To Announce Second Quarter 2017 Financial Results On August 2, 2017

  7/13/2017

• Endologix Presents Positive Two-Year Clinical Data From The Nellix EVAS FORWARD IDE Trial

  6/5/2017

• Endologix Reports Positive Clinical Data From The Ovation LUCY Study

  6/1/2017

• Why Endologix Shares Are Hitting A Multiyear Low

  5/19/2017

• Endologix Provides An Update On The Nellix Endovascular Aneurysm Sealing System U.S. Regulatory Status

  5/18/2017

• Endologix Reports First Quarter 2017 Financial Results

  5/5/2017